PERRIGO Co plc — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Perrigo entered a definitive agreement to sell its Infant Formula business to MeridianMade for $40M cash at closing plus up to $135M in contingent milestone payments through 2030. The trailing-twelve-month Infant Formula business generated $380M net sales and $8M segment adjusted operating income. Perrigo expects to record a non-cash impairment charge of $275–$375M in Q4 2026, with closing targeted for H1 2027; the transaction is expected to enhance margins, reduce future capex, and allow focus on core consumer self-care products.
Why this rating
Material portfolio streamlining (~10% of revenue divested) with modest proceeds relative to $3.7B market cap, but significant impairment charge and strategic repositioning; modest earnings contribution suggests financial benefit modest.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.